摘要
IFN-λ是新发现的分类为Ⅲ型干扰素的细胞因子,由IFN-λ1,IFN-λ2和IFN-λ3组成,也称作IL29,IL28A和IL28B.IFN-λ通过与其受体复合物结合进行信号转导,该复合物由特异性的IFN-λR1以及与IL-10相关的细胞因子共有的受体IL-10R2组成.IFN-λ主要激活Jak-STAT通路诱导抗病毒、抗增殖、抗癌以及先天或适应性免疫反应.其晶体结构与IL-10细胞因子家族相似.诱导IFN-λ基因表达的通路尚未被研究透彻,在一定程度上同IFN-α类似,涉及TRIF,RIG-I或IRF7通路.IL28B的核苷酸多态性与丙型肝炎病毒(HCV)的自发性清除及HCV联合疗法的结果有关联,预示IFN-λ可以作为替代目前IFN-α治疗HCV感染的一个更有效的选择.本文提供了IFN-λ的一些研究进展,关于IFN-λ的很多机制目前仍是未知的.
IFN-λ are newly described cytokines classified as type III interferon composed of IFN-λI, IFN-L2, IFN-λ3 （also named as IL29, IL28A, IL28B）. IFN-λs signal through the IFN-λR complex consisting of a unique ligand-binding chain, IFN-λR1 and an IL-10 related cytokine receptors shared accessory chain, IL-10R2 and activate primarily JAK-STAT pathway to induce antiviral, antitumor, anti-proliferative, innate or adaptive immunity. The crystal structure of IFN-λ, resembles topologically to the IL-10 family of cytokines. Induction of IFN-λ genes expression is to some degree similar to IFN-α through TRIF, RIG-I or IRF7 pathway whereas this remains under exploration. IL28B polymorphisms are linked to spontaneous eradication of HCV and outcomes of recombinant therapy and these implicate the use of IFN-λ, as a more effective therapeutic alternative for HCV infection compared with the current IFN-α. In this article, we provide a comprehensive review of IFN-λ which is still elusive with large amounts of mechanisms unclarified.
出处
《中国科学：生命科学》
CSCD
北大核心
2015年第2期142-155,共14页
Scientia Sinica(Vitae)
基金
国家自然科学基金(批准号:81461130019)资助项目
